查詢結果分析
來源資料
相關文獻
- Outcome of Gemcitabine Based Chemoradiation for Loco-Regional Cholangiocarcinoma
- Three-dimensional Conformal Radiotherapy for Unresectable or Post-operative Residual Biliary Tract Carcinoma
- The Outcome of Intraluminal Brachytherapy Using Iridium 192 (Ir-192) for Hepatobiliary Cancers with Biliary Tract Obstruction
- Postoperative Radiotherapy of Adult Supratentorial High-grade Astrocytoma
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- Radiation Therapy in Primary Central Nervous System Lymphoma
- Implications of a Failed Prospective Trial of Adjuvant Therapy after Radical Hysterectomy for Stage Ib-IIa Cervical Carcinoma with Pelvic Node Metastases
- 攝護腺癌之傳統放射線治療--長庚紀念醫院十四年之經驗
- Preoperative Radiotherapy in Patients with Lower Rectal Cancer:Results of Sphincter-Preservation, Treatment Outcome and Morbidities
- A Phase Ⅱ Study of Neoadjuvant Interferon Alfa-2B and Concurrent Interferon and Radiotherapy in Primary Untreated Undifferentiated Carcinoma of Nasopharynx
頁籤選單縮合
題名 | Outcome of Gemcitabine Based Chemoradiation for Loco-Regional Cholangiocarcinoma=局部區域型膽道癌之Gemcitabine同步化放療 |
---|---|
作者 | 李政彥; 楊凱琳; 柯卉玲; 楊圳隆; 林裕民; 陳瑞灝; 季匡華; | 書刊名 | 放射治療與腫瘤學 |
卷期 | 22:2 2015.06[民104.06] |
頁次 | 頁113-120 |
分類號 | 416.247 |
關鍵詞 | 膽道癌; 放射治療; Cholangiocarcinoma; Gemcitabine; Radiotherapy; |
語文 | 英文(English) |
中文摘要 | 目的:目前膽道癌的治療仍以手術為主,而同步化放療治療則用於術後之輔助性治療,或在無法手術切除病灶之病患。文獻中所記載之同步化放療療法仍以flourauracil為主,以gemcitabine進行治療者著墨不多。本文乃對於本院接受gemcitabine行同步化放療病人進行回溯性分析。材料及方法:從2004年4月至2012年12月,共有26位新診斷膽管癌病患(男/女=17/9;年齡中位數:66歲)於本院接受以gemcitabine為主的根治性同步化放療。當中22位病患體能狀態為ECOG 0-1、4位為ECOG 2,9位有淋巴轉移病灶、17位無淋巴轉移病灶。Gemcitabine使用劑量為每週或隔週 400 mg/m2,放射線劑量中位數為52.0 Gy(40-72.1 Gy)。以單變項及多變項分析找出可能的預後因子。結果:所有病患的平均存活期為13.2月,一年及二年存活率分別為53%以及8%。在單變項分析中,體能狀態為ECOG 0-1者較ECOG 2者之存活期存在顯著差異(16.9月vs. 1.5月,p=0.045)。年齡(< 66歲)雖然對平均存活期有正面影響,但未達顯著統計差異(28.0月vs.4.8月,p=0.055)。在腫瘤區復發者共八位,其中二位為單純腫瘤復發。因治療副作用死亡者共兩位。結論:以gemcitabine進行膽道管癌的同步化放療是可行的治療方式,可做為手術之外的主要治療方式。體能狀態良好的病人應可由本治療得到較長的生存期。 |
英文摘要 | Purpose: Surgery remains the primary treatment of cholangiocarcinoma, with concurrent chemoradiation (CCRT) reserved for adjuvant treatment or as primary treatment for unresectable disease. However, the experience has been limited to flourauracilbased chemoradiation. A retrospective analysis of gemcitabine based CCRT as primary treatment for loco-regional cholangiocarcinoma in our institute was performed. Materials and Methods: Between April, 2004 and December, 2012, 26 patients (M/F=17/9; median age=66years) with cholangiocarcinoma (14 intrahepatic primary and 12 perihilar or extrahepatic primary) were treated with curative intent at our department. Baseline performance status based on Eastern Cooperative Oncology Group (ECOG) was 0-1 in 22 patients and 2 in 4 patients. Nine had regional extension of the diseases (defined as metastasis in either regional or para-aortic lymph nodes), whereas 17 had localized (T1-4N0M0) disease. The median equivalent dose in 2 Gy (EQD2) was 52.0 Gy (range: 40-72.1 Gy). Concurrent chemotherapy was low dose gemcitabine at 400 mg/m2 given weekly to biweekly. Both univariateand multivariate analyses were used to identify statistically significant prognostic factors. Results: The median survival of the entire cohort was 13.2 months. Survival rates at 1 and 2 year were 53% and 8% respectively. Patients of better performance status (ECOG 0-1) had improved median survival in comparison to those who of poorer baseline performance status (ECOG 2) (16.9 months vs. 1.5 months, p=0.045) on univariate analysis. Younger age (< 66 years) trended towards improved median survival (28.0 months vs. 4.8 months, p=0.055). There was eight local failures, two of which were isolated local failures. There were two treatment-related deaths. Conclusions: Outcome of low dose gemcitabine CCRT for cholangiocarcinoma seems promising. Those with better baseline performance status are most likely to benefit from this treatment. Definitive gemcitabine based CCRT for loco-regional cholangiocarcinoma may be an alternative to primary surgery. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。